Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients

Barbui, T.; De Stefano, V.; Carobbio, A.; Iurlo, A.; Alvarez-Larran, A.; Cuevas, B.; Ferrer Marin, F.; Vannucchi, A. M.; Palandri, F.; Harrison, C.; Sibai, H.; Griesshammer, M.; Bonifacio, M.; Elli, E. M.; Trotti, C.; Koschmieder, S.; Carli, G.; Benevolo, G.; Ianotto, J. -C.; Goel, S.; Falanga, A.; Betti, S.; Cattaneo, D.; Arellano-Rodrigo, E.; Mannelli, L.; Vianelli, N.; Doyle, A.; Gupta, V.; Wille, K.; Tremblay, D.; Mascarenhas, J.

doi:10.1038/s41375-021-01279-1

In the Philadelphia-negative myeloproliferative neoplasms (MPN), the major burden of disease is the elevated risk of thrombosis [1]. Moreover, MPN patients are concomitantly prone to bleeding [1], making antithrombotic therapy challenging. Regarding atrial fibrillation (AF), very scarce data are available about treatment outcomes with vitamin-K antagonists (VKAs) or direct oral anticoagulants (DOACs) [2, 3]. On the other hand, VKAs partially prevent recurrent venous thromboembolism (VTE), and the incidence of either recurrent thrombosis and major bleeding is still unacceptable high [4].

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients / Barbui T.; De Stefano V.; Carobbio A.; Iurlo A.; Alvarez-Larran A.; Cuevas B.; Ferrer Marin F.; Vannucchi A.M.; Palandri F.; Harrison C.; Sibai H.; Griesshammer M.; Bonifacio M.; Elli E.M.; Trotti C.; Koschmieder S.; Carli G.; Benevolo G.; Ianotto J.-C.; Goel S.; Falanga A.; Betti S.; Cattaneo D.; Arellano-Rodrigo E.; Mannelli L.; Vianelli N.; Doyle A.; Gupta V.; Wille K.; Tremblay D.; Mascarenhas J.. - In: LEUKEMIA. - ISSN 0887-6924. - ELETTRONICO. - 35:(2021), pp. 2989-2993. [10.1038/s41375-021-01279-1]